Etiometry Earns Top Honors – Major Recognition Nearby and Nationally
News and Press Releases
BOSTON, December 17, 2018 – Improving the quality of critical care has always been their top priority but earning accolades along the way is an added bonus. In 2018, Etiometry earned major recognition and funding from prestigious organizations nearby and nationally.
Competing against 213 companies from five of the six New England states can be a daunting task for any business owner; but Etiometry was up for the challenge. After narrowing the competition to 50 semi-finalists, then 20 finalists, Etiometry’s COO Evan Butler presented the company’s mission in front of a 64-judge panel. Several months of deliberation went by but, ultimately, Etiometry took top honors as one of the eight winners of the 2018 New England Business Association’s Innovation Awards. “As the Circle of Excellence welcomes the class of 2018, I can honestly say it is one of our best yet”, said New England Innovation Awards Committee Chairman, Todd Faber, President, The Faber Group, in a press release.
The largest source of funding for medical research in the world continues to see value in Etiometry’s work. For the third time in four years, The National Institutes of Health awarded Etiometry nearly one million dollars to continue their groundbreaking progress in dynamic analytics for critical care facilities. The latest grant award aims to investigate how Etiometry’s FDA-cleared Risk Analytics Algorithm for Inadequate Delivery of Oxygen, known as the IDO2 Index, can best be used to inform treatment decisions. With the help of their clinical partners, the team is designing and deploying protocols and studying their critical care outcomes; such as length of stay, time on ventilation, and ECMO events. As a Boston-based company, Etiometry is proud to contribute to the city’s unparalleled 23-year record for most NIH funds.
About Etiometry
Etiometry Inc. is the leader in clinical decision-support software for the intensive care environment. Our technologies provide valuable clinical insight and analysis to support early recognition of subtle changes in patient condition to avoid complications and speed recovery. Etiometry is committed to improving patient outcomes, increasing clinical efficiency, and lowering costs of care through the more effective use of all available data.
For more information, visit www.etiometry.com.
We’d love to hear from you
Whether you’re curious about how Etiometry can help support your team, the platform’s latest outcomes data or a demo – we’re ready to answer your questions.
Contact UsRelated
Etiometry Significantly Enhances Platform Capabilities, Extending Insights Beyond the ICU
The addition of high-fidelity waveform data integration provides deeper insights and additional data points available in lower-acuity settings July 8, 2025 – BOSTON – Etiometry, a leader in clinical decision support software, has announced a significant advancement to its platform with the integration of high-fidelity waveform data to inform and improve existing clinical data interpretation. […]
Multicenter Study Demonstrates 29% Reduction in Vasoactive Infusion Time with Use of Etiometry’s AI Powered Clinical Intelligence Platform
Study published in Critical Care Medicine highlights impact of IDO2-informed decision support on reducing postoperative support duration June 17, 2025 – BOSTON – A newly published multicenter clinical trial in Critical Care Medicine shows that use of Etiometry’s Clinical Intelligence Platform—specifically its Inadequate Delivery of Oxygen (IDO2) Index—was associated with a significant reduction in the […]
Boston Children’s Hospital Multi-center Study Finds Etiometry’s Risk Analytics Algorithms May Help Assess Extubation Failure Following Congenital Cardiac Surgery
Results published in Pediatric Critical Care Medicine demonstrate that the IDO2 and IVCO2 Indices may support more informed ventilator liberation decisions May 19, 2025 – BOSTON – A newly published multi-center study has found that Etiometry’s FDA-cleared physiologic risk analytics—IDO2 and IVCO2—were found to be associated with increased risk of extubation failure in retrospective analysis, […]